S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:CRBP

Corbus Pharmaceuticals - CRBP Competitors

$6.46
-0.20 (-3.00%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$6.26
$7.01
50-Day Range
$0.14
$6.91
52-Week Range
$2.11
$18.72
Volume
133,615 shs
Average Volume
462,785 shs
Market Capitalization
$26.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

CRBP vs. LUMO, NLTX, STSA, CPIX, KALA, IMPL, LPCN, RNXT, TFFP, and MBRX

Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Lumos Pharma (LUMO), Neoleukin Therapeutics (NLTX), Satsuma Pharmaceuticals (STSA), Cumberland Pharmaceuticals (CPIX), Kala Pharmaceuticals (KALA), Impel Pharmaceuticals (IMPL), Lipocine (LPCN), RenovoRx (RNXT), TFF Pharmaceuticals (TFFP), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical preparations" industry.

Corbus Pharmaceuticals vs.

Corbus Pharmaceuticals (NASDAQ:CRBP) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.

Corbus Pharmaceuticals received 399 more outperform votes than Lumos Pharma when rated by MarketBeat users. However, 71.43% of users gave Lumos Pharma an outperform vote while only 68.72% of users gave Corbus Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Corbus PharmaceuticalsOutperform Votes
424
68.72%
Underperform Votes
193
31.28%
Lumos PharmaOutperform Votes
25
71.43%
Underperform Votes
10
28.57%

In the previous week, Lumos Pharma had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 1 mentions for Lumos Pharma and 0 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.98 beat Lumos Pharma's score of 0.76 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Corbus Pharmaceuticals Positive
Lumos Pharma Positive

Lumos Pharma has higher revenue and earnings than Corbus Pharmaceuticals. Lumos Pharma is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corbus Pharmaceuticals$880 thousand31.56-$42.35 million-$10.42-0.64
Lumos Pharma$1.52 million18.06-$31.06 million-$3.70-0.90

Corbus Pharmaceuticals currently has a consensus target price of $3.00, suggesting a potential downside of 54.95%. Lumos Pharma has a consensus target price of $17.67, suggesting a potential upside of 428.94%. Given Lumos Pharma's higher possible upside, analysts clearly believe Lumos Pharma is more favorable than Corbus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Lumos Pharma
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Corbus Pharmaceuticals has a net margin of 0.00% compared to Lumos Pharma's net margin of -2,039.53%. Lumos Pharma's return on equity of -43.80% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Corbus Pharmaceuticals N/A -80.51% -46.99%
Lumos Pharma -2,039.53% -43.80% -37.63%

18.7% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 30.5% of Lumos Pharma shares are held by institutional investors. 6.3% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 21.2% of Lumos Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Corbus Pharmaceuticals has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.

Summary

Lumos Pharma beats Corbus Pharmaceuticals on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRBP vs. The Competition

MetricCorbus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$26.94M$5.47B$4.31B$5.87B
Dividend YieldN/A2.59%2.41%4.45%
P/E Ratio-0.625.53117.0313.40
Price / Sales30.61292.643,516.7756.95
Price / CashN/A19.3627.04101.17
Price / Book0.824.164.464.95
Net Income-$42.35M$186.79M$115.18M$190.78M
7 Day Performance12.35%-3.85%-2.68%-1.48%
1 Month Performance130.71%-10.85%-6.79%-6.89%
1 Year Performance1,258.57%-14.54%-16.22%-18.46%

Corbus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LUMO
Lumos Pharma
2.1743 of 5 stars
$3.34
+3.4%
$17.67
+428.9%
-66.6%$27.46M$1.52M-0.9029Gap Up
NLTX
Neoleukin Therapeutics
2.1166 of 5 stars
$0.66
-1.5%
$6.00
+809.1%
-65.3%$28.10MN/A-0.6191Analyst Revision
News Coverage
Gap Down
STSA
Satsuma Pharmaceuticals
2.2868 of 5 stars
$0.85
flat
$7.40
+770.5%
-78.4%$28.16MN/A-0.4321Gap Down
CPIX
Cumberland Pharmaceuticals
0 of 5 stars
$1.94
-1.5%
N/A-28.7%$28.36M$42.01M-5.1183Analyst Report
Gap Down
KALA
Kala Pharmaceuticals
2.2082 of 5 stars
$14.17
-6.5%
$51.13
+260.8%
-64.4%$28.77M$3.89M-0.47192News Coverage
IMPL
Impel Pharmaceuticals
2.0003 of 5 stars
$1.13
+5.6%
$15.00
+1,232.7%
-85.9%$26.72M$670,000.00-0.24129Upcoming Earnings
Gap Down
LPCN
Lipocine
1.8789 of 5 stars
$0.33
flat
$4.00
+1,120.3%
-81.8%$29.01M$500,000.00-2.3413Analyst Report
Analyst Revision
Gap Up
RNXT
RenovoRx
0 of 5 stars
$2.90
-1.7%
N/A-4.3%$26.30MN/A-2.6610Gap Up
TFFP
TFF Pharmaceuticals
2.4424 of 5 stars
$0.75
flat
$15.67
+1,988.9%
-88.7%$26.10M$90,000.00-0.554Analyst Report
Gap Up
MBRX
Moleculin Biotech
2.0048 of 5 stars
$1.03
+5.1%
$10.50
+919.4%
-33.5%$29.49MN/A-1.1813News Coverage
This page (NASDAQ:CRBP) was last updated on 3/23/2023 by MarketBeat.com Staff